Infectious Diseases (all articles) | Page 81 of 298 | Links Medicus Content Curation & Alerts in Medicine

Vaccine apartheid: This is not the way to end the pandemic.

22 Oct, 2021 | 10:26h | UTC

Vaccine apartheid: This is not the way to end the pandemic – Journal of Paediatrics and Child Health

Commentary on Twitter

Vaccine apartheid is devastating, especially for children@VSLanziotti @yoncabulutmd @surf4children @sgdambrauskas call for everyone to advocate for vaccine equity https://t.co/jzJd9kwcCi pic.twitter.com/0hEPk8B4xv

— Madhu Pai, MD, PhD (@paimadhu) October 21, 2021

RCT: In adults with Covid-19 and severe hypoxemia, 12 mg vs. 6 mg of Dexamethasone did not result in a statistically significant difference in the number of days alive without life support.

22 Oct, 2021 | 10:32h | UTC

Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial – JAMA

Editorial: Glucocorticoid Dose in COVID-19: Lessons for Clinical Trials During a Pandemic – JAMA

Commentary on Twitter

In a randomized trial of patients with #COVID19 and severe hypoxemia, compared with 6 mg of dexamethasone, 12 mg of dexamethasone did not statistically significantly reduce the number of days alive without life support at 28 days https://t.co/BMgLTel4aU pic.twitter.com/WKwI8xCUYO

— JAMA (@JAMA_current) October 21, 2021

Opinion | Politics is derailing a crucial debate over the immunity you get from recovering from Covid-19.

22 Oct, 2021 | 10:22h | UTC

Covid-19 Politics is derailing a crucial debate over the immunity you get from recovering from Covid-19 – STAT

M-A: Risk factors for poor prognosis in children and adolescents with COVID-19.

22 Oct, 2021 | 10:24h | UTC

Risk factors for poor prognosis in children and adolescents with COVID-19: A systematic review and meta-analysis – EClinicalMedicine

Health care environmental hygiene: new insights and centers for disease control and prevention guidance.

22 Oct, 2021 | 10:07h | UTC

Health Care Environmental Hygiene: New Insights and Centers for Disease Control and Prevention Guidance – Infectious Disease Clinics of North America

Health care–acquired infections in low- and middle-income countries and the role of infection prevention and control.

22 Oct, 2021 | 10:09h | UTC

Health Care–Acquired Infections in Low- and Middle-Income Countries and the Role of Infection Prevention and Control – Infectious Disease Clinics of North America

Occupational health update: approach to evaluation of health care personnel and preexposure prophylaxis.

22 Oct, 2021 | 10:06h | UTC

Occupational Health Update: Approach to Evaluation of Health Care Personnel and Preexposure Prophylaxis – Infectious Disease Clinics of North America

An analysis of Scotland’s mortality in 114,000 SARS-CoV2–infected people revealed that the vaccine effectiveness against death from the Delta variant was 90% for the Pfizer vaccine and 91% for AstraZeneca.

21 Oct, 2021 | 10:15h | UTC

BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant – New England Journal of Medicine

Pfizer vaccine showed estimated effectiveness of 93% against symptomatic SARS-CoV-2 Delta variant infection in adolescents.

21 Oct, 2021 | 10:17h | UTC

Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents – New England Journal of Medicine

Commentary on Twitter

The remarkably high effectiveness (VE) of vaccination for teens vs the Delta variant in over 94,000 vaccinees and 94,000 matched controls: 93% VE vs symptomatic infection (95% CI 88,97) https://t.co/wwoXlw7PH9 @NEJM pic.twitter.com/8m3fJ7avc5

— Eric Topol (@EricTopol) October 20, 2021

A case-controlled study showed Covid-19 vaccination during early pregnancy was not associated with increased risk of first-trimester miscarriage.

21 Oct, 2021 | 10:14h | UTC

Covid-19 Vaccination during Pregnancy and First-Trimester Miscarriage – New England Journal of Medicine

Editorial: Covid-19 treatments and vaccines must be evaluated in pregnancy.

Cohort study: Vaccinated pregnant patients had 90% lower risk of severe or critical Covid-19 compared with unvaccinated pregnant patients.

Two observational studies suggest spontaneous abortion is not increased following COVID-19 mRNA vaccination during pregnancy.

Study shows high effectiveness of the Pfizer mRNA COVID-19 vaccine in pregnancy.

5 Crucial Things to Know About COVID-19 Vaccines and Pregnancy.

CDC Guidance: Pregnant people should be vaccinated against COVID-19.

ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – “ACOG encourages its members to enthusiastically recommend vaccination to their patients.”

Cohort study: Pfizer/BioNTech COVID vaccine associated with 78% lower risk of Covid-19 in pregnancy.

FDA authorizes booster doses of Moderna and Johnson & Johnson vaccines, says mix and match OK.

21 Oct, 2021 | 10:09h | UTC

FDA authorizes booster doses of Moderna and Johnson & Johnson vaccines, says mix and match OK – CNN

COVID-19 pneumonia: pathophysiology and management.

21 Oct, 2021 | 10:12h | UTC

COVID-19 pneumonia: pathophysiology and management – European Respiratory Review

Instead of quarantine for Covid-exposed students, some schools are trying test-to-stay.

21 Oct, 2021 | 10:08h | UTC

Instead of quarantine for Covid-exposed students, some schools are trying test-to-stay – CNN

Cluster RCT: Daily contact testing of school-based contacts was non-inferior to self-isolation for control of COVID-19 transmission.

Kids are losing school days to quarantines. Here’s a way to keep them in classrooms – “Test-to-stay could dramatically reduce close contact quarantines”.

Opinion | Data from routine Covid testing can help schools stay open this year.

CDC Study: Pfizer vaccine showed 93% effectiveness against Covid-19 hospitalization among children aged 12-18 years.

20 Oct, 2021 | 10:31h | UTC

Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021 – CDC Morbidity and Mortality Weekly Report

Commentary on Twitter (thread – click for more)

Vaccination reduced the risk of hospitalization among 12–18-year-olds by 93%, according to a new CDC study. No vaccinated adolescents died or were admitted to the ICU.

— Dr. Tom Frieden (@DrTomFrieden) October 19, 2021

Cohort Study: The effectiveness of heterologous AstraZeneca (AZ)/mRNA prime-boost vaccination was more significant (68%) compared to the effectiveness of homologous AZ/AZ vaccination (50%) against symptomatic Covid-19 infection in Sweden.

20 Oct, 2021 | 10:27h | UTC

Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study – The Lancet Regional Health Europe

Commentary: High effectiveness of mix-and-match COVID-19 vaccines – UMEA University

Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

A primer on what we know about mixing and matching Covid vaccines.

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

Commentary on Twitter

Study from Sweden assessing heterogenous vaccination in 3,445,061 individuals who received AZ as the first dose and either #pfizer, #moderna, or #AZ as second dose showed the following vaccine effectiveness:

AZ/Pfizer- 67%
AZ/Moderna- 79%
AZ/AZ- 50%https://t.co/UN0pey2kJ2

— Yan Leyfman, MD (@YLeyfman) October 19, 2021

Should You Mix and Match Your Booster Shot?

20 Oct, 2021 | 10:25h | UTC

Should You Mix and Match Your Booster Shot? – The Atlantic

Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

A primer on what we know about mixing and matching Covid vaccines.

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

RCT: Interferon does not improve outcomes for hospitalized adults with COVID-19.

20 Oct, 2021 | 10:28h | UTC

News release: Interferon does not improve outcomes for hospitalized adults with COVID-19 – NIH News Releases

Original study: Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial – The Lancet Respiratory Medicine

[Preprint] Observational study in Brazil showed the J&J vaccine adjusted effectiveness was 50.9% against any symptomatic Covid-19, 72.9% for hospitalization, 92.5% for ICU admission, 88.7% for mechanical ventilation, and 90.5% for death.

20 Oct, 2021 | 10:24h | UTC

Vaccine effectiveness of Ad26.COV2.S against symptomatic COVID-19 and clinical outcomes in Brazil: a test-negative study design – medRxiv

Covid-19: New mutation of Delta variant under close watch in UK.

20 Oct, 2021 | 10:21h | UTC

Covid-19: New mutation of Delta variant under close watch in UK – BBC

Long-term consequences of the misuse of ivermectin data.

19 Oct, 2021 | 09:56h | UTC

Long-term consequences of the misuse of ivermectin data – The Lancet Infectious Diseases

Ivermectin: How false science created a Covid ‘miracle’ drug.

Fraudulent ivermectin studies open up new battleground between science and misinformation.

The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.

Ivermectin: Cochrane’s most talked about review so far, ever. Why?

Flawed ivermectin preprint highlights challenges of COVID drug studies.

Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.

Why was a major study on ivermectin for covid-19 just retracted?

RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19.

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.

Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.

Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials

RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19

Commentary on Twitter

Ivermectin's data for Covid, checkered with inconsistencies, small/low quality clinical trials, and fraud, have long-term consequences for the drug's established and essential useshttps://t.co/NG6vpej8GP @TheLancetInfDis pic.twitter.com/Oz0FxUJetK

— Eric Topol (@EricTopol) October 18, 2021

RECOVERY Trial: In patients admitted to hospital with COVID-19, Colchicine did not reduce 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.

19 Oct, 2021 | 10:14h | UTC

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – The Lancet Respiratory Medicine

[Preprint] PRINCIPLE RCT: Colchicine does not improve time to recovery in outpatients with Covid-19 at higher risk of complications.

COLCORONA RCT: Colchicine for community-treated patients with COVID-19 – findings suggest it may lower death and hospital admission rates, but further studies are required.

[Preprint] RECOVERY Trial: Colchicine does not improve outcomes in patients admitted to hospital with COVID-19.

Systematic Review: Colchicine for the treatment of COVID‐19 – not beneficial for hospitalized patients; inconclusive evidence for the treatment of non-hospitalized patients, “probably slightly reduces the need for hospitalization or death within 28 days compared to placebo”.

19 Oct, 2021 | 10:13h | UTC

Colchicine for the treatment of COVID‐19 – Cochrane Library

[Preprint] PRINCIPLE RCT: Colchicine does not improve time to recovery in outpatients with Covid-19 at higher risk of complications.

COLCORONA RCT: Colchicine for community-treated patients with COVID-19 – findings suggest it may lower death and hospital admission rates, but further studies are required.

[Preprint] RECOVERY Trial: Colchicine does not improve outcomes in patients admitted to hospital with COVID-19.

Commentary on Twitter

JUST PUBLISHED – Is #colchicine (often used to treat #gout) an effective treatment for people with #COVID19? ➡️ https://t.co/IF1enksFpn New @CochraneHaem systematic review includes evidence from 4 RCTS with 11,525 hospitalised & 4488 non‐hospitalised people.

— The Cochrane Library (@CochraneLibrary) October 18, 2021

China’s COVID vaccines have been crucial — now immunity is waning.

19 Oct, 2021 | 09:53h | UTC

China’s COVID vaccines have been crucial — now immunity is waning – Nature

[Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”.

Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high.

Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.

COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

COVID vaccine effects wane over time but still prevent death and severe illness.

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

BJS commission on surgery and perioperative care post-COVID-19.

19 Oct, 2021 | 09:52h | UTC

BJS commission on surgery and perioperative care post-COVID-19 – British Journal of Surgery

Commentary on Twitter

The @BJSurgery commission on surgery and perioperative care post #Covid_19

🌐 Global surgical community involved

😱 Pandemic uncovers problems in healthcare systems

🧑‍🎓 Training severely damaged

🧿 Ethics committee needed at surgical oncology centreshttps://t.co/CfNk9vBPjV pic.twitter.com/vomtZ3zcql

— Giovanni Marchegiani (@Gio_Marchegiani) October 16, 2021

Editorial: Preparing for “Disease X”.

19 Oct, 2021 | 09:54h | UTC

Preparing for “Disease X” – Science

Stay Updated in Your Specialty